文章摘要

文章信息/Info

Title:: Prevalence and relative factors of clopidogrel resistance in patients undergoing coronary stenting

作者:: 白艳艳¹; 王长谦²; 周明成¹; 黄红漫¹; 1.上海市市东医院心内科，上海 200438； 2.上海交通大学附属新华医院心内科,上海 200092

Author(s):: BAI Yanyan¹; WANG Changqian²; ZHOU Mingcheng¹; HUANG Hongman¹; 1.Department of Cardiology, Shanghai Shidong Hospital, Shanghai 200438, China； 2.Department of Cardiology, Xinhua Hospital Affiliated to School of Medicine, Shanghai Jiaotong University, Shanghai, 200092, China

关键词:: 冠状动脉疾病; 氯吡格雷抵抗; 危险因素

Keywords:: coronary desease; clopidogrel resistance; risk factors

分类号:: R541.4

DOI:: -

文献标识码:: A

摘要:: 目的观察冠心病介入治疗患者的氯吡格雷抵抗的发生率及相关因素。方法利用比浊法测定5 μmol/L二磷酸腺苷（adenosine diphosphate，ADP）诱导的血小板聚集率（platelet aggregation rate,PAR）来判定是否发生氯吡格雷抵抗，并将研究对象按是否发生抵抗分组，按病例对照研究方法分析相关因素。结果冠心病患者介入治疗后氯吡格雷抵抗的发生率为24.3%。抵抗组与非抵抗组比较发现胰岛素抵抗指数（HOMAIR,5.3±3.3 vs 3.5±2.9，P<0.01）、总胆固醇\[（5.3±1.6）mmol/L vs （4.7±1.0）mmol/L，P<0.05）\]及冠脉病变程度［（65±53）分vs (31±29)分，P<0.01）\]有统计学意义。结论氯吡格雷抵抗的发生率24.3%，胰岛素抵抗、总胆固醇和冠脉病变程度可能是其相关因素。

Abstract:: AIM To assess the incidence of clopidogrel resistance in patients undergoing coronary stenting and to exolore the relative factors. METHODS Platelet reactivity was measured by 5 μmol/L ADPinduced aggregation (%) in patients undergoing coronary stenting to determine the clopidogrel resistance. The subjects with resistance and without resistance were assigned to different groups and correlation factors were analyzed and compared between the 2 groups. RESULTS The incidence of clopidogrel resistance was 243%. The HOMAIR, total cholesterol and coronary artery pathological degree were significantly different between the two groups (P<0.01). CONCLUSION The incidence of clopidogrel resistance is 24.3% and insulin resistance, total cholesterol and coronary artery pathological degree are some of the relative factors of clopidogrel resistance.

参考文献/References

［1］ Lee CH, Tan HC, Lim YT. Update on drugeluting stents for prevention of restenosis［J］. Asian Cardiovasc Thorac Ann, 2006, 14(1):75-82.

［2］ Selwyn AP. Prothrombotic and antithrombotic pathways in acute coronary syndromes ［J］. Am J Cardiol, 2003, 91(12A):3H-11H.

［3］ Gensini GG.A more meaningful scoring system for determining the severity of coronary heart disease［J］. Am J Cardiol, 1983, 51(3):606.

［4］ Guthikonda S, Lev EI, Kleiman NS. Resistance to antiplatelet therapy［J］. Curr Cardiol Rep, 2005, 7(4):242-248.

［5］ Dziewierz A, Dudek D, Heba G, et al. Interindividual variability in response to clopidogrel in patients with coronary artery disease［J］. Kardiol Pol, 2005, 62(2):108-117.

［6］ Soffer D, Moussa I, Harjai KJ, et al. Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: do we need more aggressive dosing regimens in unstable angina?［J］. Catheter Cardiovasc Interv, 2003, 59(1):21-25.

［7］邢波，陆士娟，陈漠水，等. 血清高敏C反应蛋白与急性冠脉综合征的相关性［J］. 心脏杂志, 2006, 18(4)：454-455.

［8］ Wilson PW, D’Agostino RB, Parise H, et al. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus［J］. Circulation, 2005, 112(20):3066-3072.

［9］ Hochholzer W, Trenk D, Frundi D, et al. Time dependence of platelet inhibition after a 600mg loading dose of clopidogrel in a large,unselected cohort of candidates for percutaneous coronary intervention［J］. Circulation, 2005, 111(20):2560-2564.

我们的网站为什么显示成这样？

冠心病患者介入治疗后氯吡格雷抵抗的发生率及相关因素(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

文章信息/Info

参考文献/References

备注/Memo

常用功能

导航/Navigate

工具/Tools

统计/Statistics